Last updated: August 17, 2026
Hydrocortisone butyrate is a mature, prescription topical corticosteroid with limited patent protection, broad generic availability, and stable but low-growth demand. The commercial market is driven by dermatology prescribing volume, payer reimbursement, manufacturing cost, product availability, and vehicle differentiation rather than by exclusivity.
The active ingredient is sold primarily as 0.1% topical cream, ointment, lotion, solution, and liposomal or emollient cream products. Brand products such as Locoid and Locoid Lipocream compete with generic hydrocortisone butyrate products approved through the FDA abbreviated new drug application pathway. No biosimilar risk exists because hydrocortisone butyrate is a chemically synthesized small molecule, not a biologic.
What is hydrocortisone butyrate used for?
Hydrocortisone butyrate is a medium-potency topical corticosteroid used to treat corticosteroid-responsive dermatoses, including atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other inflammatory skin disorders.
Its commercial positioning is between low-potency hydrocortisone products and higher-potency topical corticosteroids such as betamethasone valerate, fluocinonide, and clobetasol. The product’s value depends heavily on the vehicle and site of application.
| Attribute |
Hydrocortisone butyrate |
| Active ingredient |
Hydrocortisone butyrate |
| Typical strength |
0.1% |
| Drug class |
Topical corticosteroid |
| Common dosage forms |
Cream, ointment, lotion, solution, emollient cream |
| FDA status |
Prescription drug |
| Primary therapeutic area |
Dermatology |
| Regulatory pathway for generics |
ANDA |
| Biosimilar exposure |
None |
| Market maturity |
Mature and genericized |
| Principal commercial risk |
Generic price erosion and substitution |
FDA labeling identifies hydrocortisone butyrate as a topical corticosteroid for inflammatory and pruritic corticosteroid-responsive dermatoses. Treatment duration, body surface area, patient age, and application site affect safety and prescribing decisions.[1]
What products contain hydrocortisone butyrate?
The market includes legacy branded products and generic equivalents. Locoid and Locoid Lipocream have historically provided the principal brand reference points in the United States, while generic manufacturers compete through lower prices and supply availability.
Principal dosage forms and commercial roles
| Dosage form |
Commercial role |
Key competitive factor |
| Cream |
Broad outpatient use |
Price, texture, tolerability |
| Ointment |
Dry or thickened lesions |
Occlusiveness and efficacy |
| Lotion |
Hair-bearing areas and larger surfaces |
Spreadability and cosmetic acceptability |
| Solution |
Scalp and selected body sites |
Ease of application |
| Lipocream or emollient cream |
Brand differentiation |
Moisturization, vehicle, patient preference |
The active ingredient itself has limited differentiation. Manufacturers can obtain commercial advantages through formulation, packaging, preservative systems, dispensing systems, and supply reliability. Those advantages generally do not create a durable barrier comparable with an active pharmaceutical ingredient patent.
What is the FDA regulatory status of hydrocortisone butyrate?
Hydrocortisone butyrate is regulated as a prescription topical corticosteroid in the United States. Approved products include legacy new drug applications and generic products approved under ANDAs.
FDA approval is product-specific. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable topical drug standards. For semisolid dermatologic products, the regulatory burden can include formulation sameness, in vitro release testing, comparative characterization, and, where required, clinical or pharmacodynamic evidence.
The regulatory position creates two market effects:
- Generic substitution is structurally feasible once an ANDA is approved.
- Formulation changes can require meaningful development work even when the active ingredient is old.
The FDA Orange Book remains the principal source for marketed application status, therapeutic equivalence ratings, and listed patents or exclusivity. The market is not dependent on a current new chemical entity exclusivity period.[2]
What is the Orange Book status of hydrocortisone butyrate?
Hydrocortisone butyrate products are primarily exposed to generic substitution rather than current brand exclusivity. Legacy brand products may remain listed in FDA databases, but their commercial position does not depend on an unexpired active-ingredient patent.
The practical Orange Book assessment is:
| Issue |
Market implication |
| Reference-listed drug status |
Supports generic development |
| Generic availability |
Reduces brand pricing power |
| NCE exclusivity |
Not commercially relevant for this mature ingredient |
| Pediatric exclusivity |
Not a current market driver |
| Listed patent protection |
No longer the central barrier to entry |
| Therapeutic equivalence |
Enables pharmacy substitution where state and payer rules permit |
Patent listings can vary by product, dosage form, and regulatory history. Any transaction or litigation analysis should therefore review the current Orange Book entry for each reference product rather than rely on the active ingredient name alone.[2]
What patents protect hydrocortisone butyrate products?
The original patent estate for hydrocortisone butyrate products is effectively a historical matter. The core active ingredient and legacy product patents are old relative to the current generic market. Commercial protection now comes from manufacturing know-how, formulation execution, regulatory files, trademarks, and distribution relationships.
Formulation patents
A company may seek protection for:
- Emulsion or liposomal vehicles
- Enhanced skin penetration systems
- Preservative combinations
- Foam, spray, or other delivery formats
- Reduced-irritation formulations
- Packaging that limits contamination or improves dosing
These rights would protect a specific formulation or delivery system, not hydrocortisone butyrate generally. Their value depends on whether the formulation produces a clinically meaningful or commercially visible advantage and whether generic applicants can design around the claims.
Method-of-use patents
Method-of-use protection could cover a specific patient population, disease subtype, dosing schedule, or treatment duration. Such patents are less significant for a mature topical corticosteroid unless they are listed in the Orange Book and supported by a commercially important label indication.
No broad, current market barrier comparable with a live composition-of-matter patent should be assumed for hydrocortisone butyrate.
When did hydrocortisone butyrate lose exclusivity?
Hydrocortisone butyrate lost meaningful market exclusivity years ago. The product is now in the mature generic phase, with multiple approved or historically approved manufacturers and no NCE-driven pricing period.
The relevant exclusivity timeline is:
| Period |
Commercial condition |
| Initial launch period |
Brand-led market with limited competition |
| Patent-protected period |
Brand pricing supported by product and formulation rights |
| Generic entry period |
ANDA competition and pharmacy substitution |
| Current market |
Mature generic market with price and supply competition |
A precise single “loss of exclusivity” date is less useful than the product-by-product approval history because cream, ointment, lotion, solution, and emollient products entered the market at different times. The financial conclusion is consistent across forms: exclusivity is no longer the main value driver.
How many patents cover hydrocortisone butyrate?
The number of commercially relevant active patents is likely low or zero for the underlying active ingredient. Patent counts can be misleading because historical patents, expired formulation claims, abandoned applications, and patents covering individual products may appear in different databases.
For diligence purposes, patents should be classified into four groups:
- Expired active-ingredient patents.
- Expired or nonblocking formulation patents.
- Potentially active formulation or delivery patents.
- Orange Book-listed patents tied to a specific reference product.
Only the third and fourth groups can materially affect current entry risk. The active ingredient name alone does not establish a blocking patent position.
Which companies are competing in hydrocortisone butyrate?
Competition comes from three groups.
Brand and specialty dermatology companies
Brand owners compete through:
- Physician familiarity
- Formulation feel
- Patient adherence
- Commercial dermatology salesforces
- Distribution and payer contracting
The brand can retain a niche where physicians prefer a particular vehicle or where patients perceive better tolerability. The brand’s ability to maintain premium pricing is limited when therapeutically equivalent generics are readily available.
Generic manufacturers
Generic companies compete on:
- Wholesale acquisition cost
- Medicaid and commercial reimbursement
- Pharmacy benefit formulary position
- Manufacturing scale
- Back-order avoidance
- Contract pricing
Topical generics can experience episodic price increases when a small number of suppliers encounter manufacturing, quality, or raw-material problems. Those increases are usually supply events rather than evidence of durable market power.
Adjacent corticosteroid products
Hydrocortisone butyrate also competes with alternative topical steroids. Physicians can move patients to desonide, hydrocortisone valerate, triamcinolone acetonide, betamethasone products, fluocinolone acetonide, or clobetasol depending on potency, body site, age, lesion severity, and payer coverage.
This substitution makes the market more competitive than a simple brand-versus-generic analysis suggests.
What is the financial trajectory for hydrocortisone butyrate?
Hydrocortisone butyrate is best characterized as a stable, low-growth, price-sensitive pharmaceutical market. Public-company filings generally do not report revenue for this active ingredient separately. Sales are often aggregated into broader dermatology, prescription products, or generic portfolios.
Revenue trajectory
| Financial stage |
Expected trajectory |
| Brand launch |
High price, low-to-moderate volume |
| Generic entry |
Rapid price erosion and share fragmentation |
| Mature generic phase |
Stable unit demand, lower revenue per prescription |
| Supply disruption |
Temporary price and revenue volatility |
| Long-term outlook |
Low nominal growth, limited innovation premium |
Unit demand is supported by the persistent prevalence of eczema, dermatitis, and other inflammatory skin conditions. Revenue growth is constrained by generic substitution, low-cost alternatives, formulary pressure, and the absence of meaningful exclusivity.
The most attractive financial profile is usually held by a manufacturer with low production costs, efficient regulatory operations, and reliable supply. A brand owner without a differentiated vehicle or strong payer position faces declining prescription volume and lower net pricing.
What are the main market dynamics?
Generic price erosion
Topical corticosteroid markets typically experience price pressure after multiple ANDA entrants enter the market. The extent of erosion depends on supplier count, pharmacy substitution, payer concentration, and product complexity.
Creams and ointments are relatively accessible dosage forms. More complex vehicles can sustain better pricing if they require specialized development or have fewer approved competitors.
Vehicle differentiation
Hydrocortisone butyrate is not interchangeable from a patient-experience standpoint across every vehicle. Ointments are more occlusive, lotions spread more easily, and emollient creams may improve perceived moisturization. These differences support modest segmentation but rarely support durable premium pricing without strong clinical or adherence evidence.
Dermatology prescribing trends
Demand is linked to chronic and recurrent diseases rather than one-time treatment. Atopic dermatitis creates recurring prescription demand, but physicians may reduce long-term topical corticosteroid exposure through steroid-sparing agents such as tacrolimus, pimecrolimus, crisaborole, and newer topical or systemic therapies.
The growth of biologics and oral targeted therapies for moderate-to-severe atopic dermatitis has limited impact on the mild-to-moderate disease segment where topical corticosteroids remain common. Hydrocortisone butyrate retains relevance in localized or less severe disease.
Manufacturing and supply barriers
The principal manufacturing barriers include:
- Consistent particle size and dispersion
- Semisolid uniformity
- Microbial control
- Tube filling and packaging performance
- Stability across the product shelf life
- Validated topical release testing
- Reliable supply of pharmaceutical-grade raw materials
These are execution barriers, not strong exclusivity barriers. A manufacturer with a robust topical platform may achieve better margins than a company entering with a single product and limited scale.
What generic entry risks exist for hydrocortisone butyrate?
Generic entry risk is high because the product is mature and the active ingredient is well established. The main risks to a branded product are:
- Additional ANDA approvals
- Pharmacy-level substitution
- Formulary exclusion
- Wholesale price reductions
- Loss of physician differentiation
- Contract manufacturing competition
- Product discontinuations followed by rapid replacement
The principal risks to a generic manufacturer are different. They include low margins, competitive bidding, supply interruptions, regulatory observations, recalls, and dependence on a small number of customers.
A generic launch is most likely to succeed when the entrant offers a differentiated vehicle, secures stable manufacturing capacity, or enters during a supply shortage. A plain cream or ointment with several established suppliers has lower long-term margin potential.
Are there Paragraph IV challenges or patent litigation?
Paragraph IV litigation is not the principal current market issue for hydrocortisone butyrate. The relevant patent estate is old, and the market has already transitioned to generic competition.
A Paragraph IV certification may have been used historically for individual reference products or formulation patents, but no current litigation should be inferred from the active ingredient alone. Litigation exposure must be assessed at the NDA, dosage-form, and patent-claim level.
No major current patent dispute is a central driver of the overall hydrocortisone butyrate market. The more material legal issues are likely to involve:
- Product liability
- Manufacturing quality
- Labeling
- Advertising claims
- Supply agreements
- Trademark rights
- Distribution contracts
Is there biosimilar risk for hydrocortisone butyrate?
No. Hydrocortisone butyrate is a small-molecule drug. Competitors enter through generic drug applications, not biosimilar applications under the Public Health Service Act.
This distinction lowers regulatory complexity relative to biologic dermatology products. It also increases substitution risk because therapeutically equivalent generic products can compete directly on price.
Are licensing deals affecting hydrocortisone butyrate?
No major publicly disclosed licensing transaction appears to define the current value of hydrocortisone butyrate as a standalone asset. The ingredient may be included in broader dermatology portfolio transactions, contract manufacturing arrangements, or rights transfers, but companies generally do not report separate deal economics for this mature product.
Transaction value is more likely to reflect:
- The number of approved topical products
- Manufacturing capacity
- Customer contracts
- Regulatory dossiers
- Geographic rights
- Portfolio synergies
The active ingredient itself is unlikely to command a meaningful upfront payment without a differentiated formulation or an established distribution platform.
How does hydrocortisone butyrate compare with competing topical steroids?
| Product |
Relative commercial position |
Main advantage |
| Hydrocortisone butyrate 0.1% |
Medium-potency, mature generic |
Established efficacy and dosage-form range |
| Hydrocortisone |
Low potency, often lower cost |
Broad use and lower potency |
| Desonide |
Low potency |
Pediatric and sensitive-site positioning |
| Hydrocortisone valerate |
Medium potency |
Familiar alternative |
| Triamcinolone acetonide |
Medium potency |
Broad generic availability |
| Betamethasone valerate |
Medium to high potency |
Greater potency in selected indications |
| Fluocinonide |
High potency |
Severe inflammatory disease |
| Clobetasol |
Very high potency |
Short-duration treatment of severe lesions |
Hydrocortisone butyrate competes most directly with hydrocortisone valerate, triamcinolone acetonide, and desonide. Its commercial position depends on the balance between potency, tolerability, vehicle, price, and body-site suitability.
What is the geographic coverage of hydrocortisone butyrate?
Hydrocortisone butyrate has international potential, but market value varies by country because regulatory classifications, brand names, reimbursement rules, and topical corticosteroid prescribing practices differ.
The United States is commercially important because of its large prescription dermatology market and generic substitution system. European and other markets may classify products differently or place greater emphasis on national reimbursement and physician prescribing. Local regulatory approval and product registration are required; U.S. FDA approval does not create automatic foreign market access.
Geographic expansion is more attractive for a portfolio owner with existing dermatology registrations and distribution infrastructure than for a single-product entrant.
Key Takeaways
- Hydrocortisone butyrate is a mature prescription topical corticosteroid with broad generic competition.
- The core active ingredient is not protected by a commercially meaningful current patent barrier.
- The FDA market is driven by ANDA competition, therapeutic equivalence, payer pricing, and supply reliability.
- Brand value depends on formulation, vehicle, physician familiarity, and patient tolerability.
- No biosimilar risk exists because hydrocortisone butyrate is a small molecule.
- Public filings generally do not disclose standalone revenue for the ingredient.
- Long-term financial performance is likely to show stable unit demand, declining or flat net pricing, and limited revenue growth.
- The strongest commercial opportunity lies in efficient manufacturing, differentiated delivery systems, or portfolio-level distribution rather than in the active ingredient alone.
- Generic launch risk is high, while current Paragraph IV and patent-litigation risk is comparatively limited.
- Competitive pressure from other topical corticosteroids and steroid-sparing dermatology therapies will limit pricing power.
FAQs
What is the potency of hydrocortisone butyrate cream?
Hydrocortisone butyrate 0.1% is generally classified as a medium-potency topical corticosteroid, although potency can vary by vehicle and testing methodology.
Is hydrocortisone butyrate available over the counter?
In the United States, hydrocortisone butyrate is generally marketed as a prescription product. Lower-potency hydrocortisone products are available over the counter, but they are not equivalent to hydrocortisone butyrate in regulatory status or clinical positioning.
Can pharmacies substitute generic hydrocortisone butyrate for Locoid?
Substitution depends on the specific generic product, FDA therapeutic-equivalence rating, state law, payer rules, and the prescribed dosage form. Cream, ointment, lotion, and emollient products should not be treated as interchangeable solely because they contain the same active ingredient.
What would increase the value of a hydrocortisone butyrate product?
A differentiated vehicle, strong patient adherence data, reliable manufacturing, broad regulatory registrations, and payer access could increase value. A plain generic product with several established competitors would have limited standalone strategic value.
Does hydrocortisone butyrate compete with topical biologics?
It competes indirectly with topical and systemic nonsteroidal therapies used for inflammatory skin disease. Its core market remains patients treated with conventional topical corticosteroids, while biologics and targeted therapies are more relevant to moderate-to-severe or refractory disease.
References
-
U.S. Food and Drug Administration. (2023). Hydrocortisone butyrate topical cream, ointment, lotion, and solution prescribing information. FDA Drugs@FDA and product labeling databases.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug application requirements. https://www.fda.gov/drugs/generic-drugs
-
U.S. Food and Drug Administration. (2024). Topical dermatologic drug products and product quality guidance. https://www.fda.gov/drugs/pharmaceutical-quality-resources
-
American Academy of Dermatology. (2023). Atopic dermatitis clinical guidelines and topical corticosteroid treatment guidance. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
